- Home
- WALD vs IGMS Comparison
WALD vs IGMS Comparison
Compare WALD & IGMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WALD
- IGMS
- Stock Information
- Founded
- WALD 1988
- IGMS 1993
- Country
- WALD United Kingdom
- IGMS United States
- Employees
- WALD N/A
- IGMS N/A
- Industry
- WALD Package Goods/Cosmetics
- IGMS Biotechnology: Pharmaceutical Preparations
- Sector
- WALD Consumer Discretionary
- IGMS Health Care
- Exchange
- WALD Nasdaq
- IGMS Nasdaq
- Market Cap
- WALD 404.2M
- IGMS 348.5M
- IPO Year
- WALD 2021
- IGMS 2019
- Fundamental
- Price
- WALD $3.03
- IGMS $1.71
- Analyst Decision
- WALD Strong Buy
- IGMS Hold
- Analyst Count
- WALD 4
- IGMS 8
- Target Price
- WALD $5.95
- IGMS $6.14
- AVG Volume (30 Days)
- WALD 82.7K
- IGMS 783.1K
- Earning Date
- WALD 08-27-2024
- IGMS 03-06-2025
- Dividend Yield
- WALD N/A
- IGMS N/A
- EPS Growth
- WALD N/A
- IGMS N/A
- EPS
- WALD N/A
- IGMS N/A
- Revenue
- WALD $240,382,000.00
- IGMS $2,918,000.00
- Revenue This Year
- WALD $27.29
- IGMS $23.57
- Revenue Next Year
- WALD $19.54
- IGMS $192.36
- P/E Ratio
- WALD N/A
- IGMS N/A
- Revenue Growth
- WALD N/A
- IGMS 57.64
- 52 Week Low
- WALD $2.41
- IGMS $1.59
- 52 Week High
- WALD $9.46
- IGMS $22.50
- Technical
- Relative Strength Index (RSI)
- WALD 37.47
- IGMS 19.36
- Support Level
- WALD $2.96
- IGMS $1.59
- Resistance Level
- WALD $3.15
- IGMS $2.06
- Average True Range (ATR)
- WALD 0.21
- IGMS 0.41
- MACD
- WALD -0.06
- IGMS -0.25
- Stochastic Oscillator
- WALD 23.57
- IGMS 2.18
About WALD Waldencast plc
Waldencast PLC is a beauty and wellness operating platform by developing, acquiring, accelerating, and scaling the next generation of conscious, purpose-driven brands. It is organized into two reportable segments namely Obagi Skincare and Milk Makeup.
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.